Fluvastatin (sodium salt) (CAS 93957-55-2) || Cayman Chemical

Fluvastatin (sodium salt)

Cayman Chemical Item Number 10010337

(CAS 93957-55-2)

Fluvastatin (sodium salt) (CAS 93957-55-2)

Description

Hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase is the rate-limiting enzyme in the cholesterol biosynthetic pathway and the target of the “statin” class of cholesterol-lowering drugs.¹ Fluvastatin acts as a competitive inhibitor of HMG-CoA reductase with respect to binding of the substrate HMG-CoA (K_i = 0.3 nM) but not with respect to binding of NADPH.^2,3 It is marketed under the trade name Lescol for the treatment of hypercholesterolemia in the prevention of cardiovascular disease. When fluvastatin was administered in a clinical trial to patients undergoing percutaneous coronary intervention, LDL cholesterol levels were reduced by 27% after six weeks of treatment with a dose of 40 mg/kg twice a day compared to placebo.⁴

1 Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2 517-526 (2003).

2 Istvan, E.S., and Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 1160-1164 (2001).

3 Corsini, A., Maggi, F.M., and Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31(1) 9-27 (1995).

4 Serruys, P.W.J.C., de Feyter, P., Macaya, C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287(24) 3215-3222 (2002).

Formal Name

7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid, sodium salt

CAS Number

93957-55-2

Molecular Formula

C₂₄H₂₅FNO₄ · Na

Formula Weight

433.5

Formulation

A crystalline solid

Purity

≥98%

λ_max

233, 305 nm

Stability

2 years

Storage

-20°C

Shipping

Room temperature in continental US; may vary elsewhere

SMILES

Copy SMILES to clipboard

[Na].OC(=O)CC(O)CC(O)/C=C/c1c(c2ccc(F)cc2)c2ccccc2n1C(C)C

Background Reading

Tobert, J.A. Lovastatin and beyond: The history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2 517-526 (2003).

Corsini, A., Maggi, F.M., and Catapano, A.L. Pharmacology of competitive inhibitors of HMG-CoA reductase. Pharmacol Res 31(1) 9-27 (1995).

Serruys, P.W.J.C., de Feyter, P., Macaya, C., et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287(24) 3215-3222 (2002).

Istvan, E.S., and Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 292 1160-1164 (2001).

Show all 4 Hide all but first 3

Size

Price

Quantity

Subtotal

10 mg 
$20.00

$0.00

25 mg 
$44.00

$0.00

50 mg 
$66.00

$0.00

100 mg 
$118.00

$0.00

Bulk
Contact

Cart Total

$0.00

Other Resources

Management Team Company Profile Company History ChemAssistant Tools FAQs

Cayman Europe Cayman Pharma CaBRI Cayman Gear Press Releases

Illustrations and Charts Key Research Area Posters Article Library Analysis Tools Conference Schedule

Order Terms Browser Recommendation Privacy Statement Site Map

Fluvastatin (sodium salt)

Fluvastatin (sodium salt) (CAS 93957-55-2)

Description

Background Reading

Related Products

Downloads

Batch-specific Information

Fluvastatin (sodium salt)

Fluvastatin (sodium salt) (CAS 93957-55-2)

Description

Background Reading

Related Products

Downloads

Batch-specific Information

Quick Search